As of June 8, 2025, Sunshine Biopharma Inc (SBFM) reports a ROE (Return on Equity) of -21.85%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Sunshine Biopharma Inc's ROE (Return on Equity)
Over recent years, Sunshine Biopharma Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -21.85% |
| 2023-12-31 | -21.25% |
| 2022-12-31 | -123.65% |
| 2021-12-31 | -5866.04% |
| 2020-12-31 | 291.52% |
This slight upward trend highlights how Sunshine Biopharma Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Sunshine Biopharma Inc's ROE (Return on Equity) to Peers
To better understand Sunshine Biopharma Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Sunshine Biopharma Inc (SBFM) | -21.85% |
| Oragenics Inc (OGEN) | 4987.46% |
| Cyclacel Pharmaceuticals Inc (CYCC) | 515.73% |
| Multicell Technologies Inc (MCET) | 263.43% |
| Rasna Therapeutics Inc (RASP) | 227.13% |
| Xynomic Pharmaceuticals Holdings Inc (XYNO) | 111.26% |
Compared to its competitors, Sunshine Biopharma Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.